Illumina, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Illumina, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 5.1 times. Higher than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
5.1×Over the last 3 years its own operating cash covered its investment spending (capex) 5.1 times.
Higher than 87% of Healthcare companies in United States.
Cash Locked Ratio
$25For every $100 of sales, $25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $19 tied up three years earlier.
More money tied up than 53% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 5%
Sales fell 5% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-5% / -46%In 3 years sales changed by -5% while total assets changed by -46%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
2.2×Debt due within a year is covered 2.2 times by its yearly operating cash.
Higher than 74% of Healthcare companies in United States.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 71% of Healthcare companies in United States.
Tangible Assets Ratio
80%Of every $100 the company owns, $80 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 51% of Healthcare companies in United States.
Tangible Net Worth Ratio
51%Of every $100 of net worth, $51 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 52% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Illumina, Inc. owes $0.59 for every $1 it owns. Illumina, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
50.3Investors pay $50.3 for every $1 of Illumina, Inc.'s yearly profit, higher than 80% of Healthcare companies in United States.
P/B ratio
15.20The share price is 15.20 times Illumina, Inc.'s book value per share, higher than 91% of Healthcare companies in United States.
Market cap
$40.7 BThe total market value of all of Illumina, Inc.'s shares at today's price (share price × number of shares), larger than 96% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$2.7 BWhat Illumina, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$17.72Net worth divided by the number of shares. The share price of $269.40 is 15.2 times this, which is the P/B above.
Return on equity (ROE)
32.3%Illumina, Inc. earned 32.3% on its shareholders' money over the last year, higher than 94% of Healthcare companies in United States.
Owes vs Owns
0.59×Illumina, Inc. owes $0.59 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Dividend yield
NoneIllumina, Inc. does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Profit growth
Back to profitIllumina, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
19.6%Illumina, Inc. keeps $20 of every $100 of revenue as net profit.
Cash quality
1.3×Cash from Illumina, Inc.'s business was 1.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
8.1×Illumina, Inc.'s operating profit covered its interest costs 8.1 times in the year to Dec 2025.
Cash vs debt
Net debtIllumina, Inc. had $920 M more debt than cash (net debt) at Dec 2025.
Questions
What is Illumina, Inc.'s P/E ratio?
Investors pay $50.3 for every $1 of Illumina, Inc.'s yearly profit, higher than 80% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Illumina, Inc.: $40.7 B ÷ $2.7 B (31 Mar 2026) = 15.2.
What is Illumina, Inc.'s return on equity?
Illumina, Inc. earned 32.3% on its shareholders' money over the last year, higher than 94% of Healthcare companies in United States.
How much does Illumina, Inc. owe compared with what it owns?
Illumina, Inc. owes $0.59 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Does Illumina, Inc. pay a dividend?
No. Illumina, Inc. does not currently pay a dividend.
Is Illumina, Inc.'s revenue growing?
Revenue fell 1% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.